FibroGen, Inc.
NASDAQ Global SelectTotal Valuation
FibroGen, Inc. carries a market capitalization of 36.69M, placing it among publicly traded companies globally. Its enterprise value stands at -33.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.69M |
| Enterprise Value | -33.98M |
Share Statistics
FibroGen, Inc. currently has 4.05M shares outstanding.
| Shares Outstanding | 4.05M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
FibroGen, Inc. trades at a trailing price-to-earnings ratio of 0.23. The price-to-sales ratio is -0.42, and the price-to-book ratio stands at -0.03.
| PE Ratio | 0.23 |
| PS Ratio | -0.42 |
| PB Ratio | -0.03 |
| P/TBV Ratio | 2.83 |
| P/FCF Ratio | -2.96 |
| P/OCF Ratio | -2.93 |
Enterprise Valuation
| EV / Sales | 3.98 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
FibroGen, Inc. maintains a current ratio of 3.71, meaning it holds 3.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 3.71 |
| Quick Ratio | 3.56 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | 682.51 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | 107.44 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | -1.47 |
Taxes
| Income Tax | -142,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
FibroGen, Inc.'s stock has declined approximately -23.71741% over the past 52 weeks. The 50-day moving average sits at 9.14, while the 200-day moving average is 8.84.
| Beta (5Y) | N/A |
| 52-Week Price Change | -23.71741% |
| 50-Day Moving Average | 9.14 |
| 200-Day Moving Average | 8.84 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, FibroGen, Inc. generated -118.09M in revenue and converted that into 215.65M in net income, yielding earnings per share of -32.46. EBITDA reached -121.49M, while operating income came in at -122.58M.
| Revenue | -118.09M |
| Gross Profit | -97.71M |
| Operating Income | -122.58M |
| Pretax Income | -128.61M |
| Net Income | 215.65M |
| EBITDA | -121.49M |
| EBIT | -122.58M |
| Earnings Per Share (EPS) | -32.46 |
Balance Sheet
Total book value stands at -1.69B, with working capital of 97.45M providing operational flexibility.
| Cash & Cash Equivalents | 117.98M |
| Total Debt | N/A |
| Net Debt | -117.97M |
| Equity (Book Value) | -1.69B |
| Book Value Per Share | -418.59 |
| Working Capital | 97.45M |
Cash Flow
FibroGen, Inc. produced -16.91M in operating cash flow over the past twelve months. After subtracting -179,000.00 in capital expenditures, free cash flow totaled -17.09M - equivalent to -4.23 per share.
| Operating Cash Flow | -16.91M |
| Capital Expenditures | -179,000.00 |
| Free Cash Flow | -17.09M |
| FCF Per Share | -4.23 |
Margins
FibroGen, Inc. operates with a gross margin of 82.74, reflecting its pricing power and cost economics. The operating margin of 103.80 and net profit margin of -182.61 provide insight into operational efficiency.
| Gross Margin | 82.74 |
| Operating Margin | 103.80 |
| Pretax Margin | 108.91 |
| Profit Margin | -182.61 |
| EBITDA Margin | 102.87 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 173.82 |
| FCF Yield | -33.82 |
Stock Splits
FibroGen, Inc.'s most recent stock split took place on June 17, 2025 with a 25:1 split ratio.
| Last Split Date | 6/17/2025 |
| Split Ratio | 25:1 |
Scores
FibroGen, Inc. posts an Altman Z-Score of -20.00, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -20.00 |